<DOC>
	<DOC>NCT02990403</DOC>
	<brief_summary>In this clinical cohort study, the investigators are going to observe the efficacy of anti-coagulation and immune therapy in the treatment of recurrent pregnancy loss with a prospective randomized controlled trial.</brief_summary>
	<brief_title>The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss</brief_title>
	<detailed_description />
	<mesh_term>Abortion, Spontaneous</mesh_term>
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dydrogesterone</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Woman who had 2 miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form. 1. having experienced severe allergies, trauma history and/or operation history within 3 months. 2. with a history of mental illness and/or family history of mental illness limb disabled. 3. taking medicine within one month. 4. suffering major events or having mood swings. 5. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine routine) 6. chromosome aberrations in anyone of the couple. 7. patients who have drugs contraindications</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>